Le Lézard
Classified in: Health, Science and technology, Business
Subjects: NPT, LIC

EVERSANAtm joins phactMI Corporate Partner Program, helping to shape the future of medical information services


PHILADELPHIA and CHICAGO, Oct. 5, 2021 /PRNewswire/ -- The Pharma Collaboration for Transparent Medical Information, known as phactMItm, announced today the membership of EVERSANAtm, the pioneer of next generation commercial services to the global life sciences industry, as a Corporate Partner.

In the newly created Corporate Partner membership model, EVERSANA joins a limited network of MI service providers with the infrastructure and expertise to shape the future of Medical Information. The Partner program will collaborate with phactMI's members, including pharmaceutical company MI leaders to drive initiatives that will support healthcare professionals and patients in a rapidly changing world. The Partner network will also provide immediate access to leaders, resources and technology for healthcare professionals as they focus on quality patient care.

"We hope to further evolve phactMI to enable greater access of medical information for healthcare professionals. We welcome EVERSANA as a Corporate Partner to help us achieve this goal!" ? Patrick Reilly, CEO, phactMI

"This sector is advancing by the minute and we applaud phactMI's efforts to help healthcare providers provide safe and effective care to patients worldwide," said Jim Lang, CEO, EVERSANA Building upon more than 20 years of MI service excellence, we are humbled to join this organization and work with its members on transformative initiatives and services to advance next generation medical information services," said Jim Lang, CEO, EVERSANA.

Media Contacts:
EVERSANA
Sarah Zwicky
Tel +1 (414) 434-4691

About phactMI

phactMI is a not-for-profit 501(c)(6) organization. phactMI is funded by phactMI member companies and all activities of phactMI are reviewed and agreed-upon by the member companies, in accordance with the organizational by-laws. phactMI is dedicated to supporting healthcare professionals in their commitment to provide quality patient care. See more at www.phactmi.org

About EVERSANA

EVERSANAtm is the leading provider of global services to the life sciences industry. The company's integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 500 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit eversana.com or connect through LinkedIn and Twitter.

SOURCE Eversana


These press releases may also interest you

at 22:03
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

at 22:00
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

at 21:45
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...

at 21:30
The "Whole Genome and Exome Sequencing Markets by Application, Organism and Product with Executive and Consultant Guides. Includes Direct to Consumer Analysis. 2023 to 2027" report has been added to  ResearchAndMarkets.com's offering. Will all...

at 20:50
Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue was RMB63.5 million, the R&D investment was RMB372 million, the cash and cash equivalent at the end of 2023 was...

at 20:35
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company announced that the first patient in China has been dosed in the Phase 1b clinical study of the combination of InnoCare's novel SHP2 (Src Homology 2 domain containing...



News published on and distributed by: